{
  "guideline": {
    "id": "PA166104988",
    "name": "Annotation of DPWG Guideline for haloperidol and CYP2D6",
    "objCls": "Guideline Annotation",
    "source": "DPWG",
    "version": 33,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104988",
    "relatedChemicals": [
      {
        "id": "PA449841",
        "name": "haloperidol",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302410",
      "name": "Recommendation Annotation PA166302410",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103989,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302401",
      "name": "Recommendation Annotation PA166302401",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103980,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The genetic variation results in a higher plasma concentration, but the effect is small and no clinically significant effects were found."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302414",
      "name": "Recommendation Annotation PA166302414",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103993,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302405",
      "name": "Recommendation Annotation PA166302405",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103984,
        "html": "<p>The guideline does not provide a recommendation for haloperidol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on haloperidol."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302409",
      "name": "Recommendation Annotation PA166302409",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103988,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302400",
      "name": "Recommendation Annotation PA166302400",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103979,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The genetic variation results in a higher plasma concentration, but the effect is small and no clinically significant effects were found."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302413",
      "name": "Recommendation Annotation PA166302413",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103992,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302404",
      "name": "Recommendation Annotation PA166302404",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103983,
        "html": "<p>The guideline does not provide a recommendation for haloperidol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on haloperidol."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302399",
      "name": "Recommendation Annotation PA166302399",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103978,
        "html": "<p>Use 60% of the normal dose.</p>\n"
      },
      "implications": [
        "There are indications for an increased risk of side effects. The genetic variation leads to decreased conversion of haloperidol, resulting in plasma concentrations that are approximately 1.7-fold higher."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302408",
      "name": "Recommendation Annotation PA166302408",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103987,
        "html": "<p>The guideline does not provide a recommendation for haloperidol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on haloperidol."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302412",
      "name": "Recommendation Annotation PA166302412",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103991,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302403",
      "name": "Recommendation Annotation PA166302403",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103982,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The genetic variation results in a higher plasma concentration, but the effect is small and no clinically significant effects were found."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302416",
      "name": "Recommendation Annotation PA166302416",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103995,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302407",
      "name": "Recommendation Annotation PA166302407",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103986,
        "html": "<p>The guideline does not provide a recommendation for haloperidol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on haloperidol."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302411",
      "name": "Recommendation Annotation PA166302411",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103990,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302402",
      "name": "Recommendation Annotation PA166302402",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103981,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The genetic variation results in a higher plasma concentration, but the effect is small and no clinically significant effects were found."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302415",
      "name": "Recommendation Annotation PA166302415",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103994,
        "html": "<p>Use 1.5 times the normal dose or choose an alternative.</p>\n<p>Antipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine.</p>\n"
      },
      "implications": [
        "There are indications of a risk of reduced effectiveness. The genetic variation leads to an increased conversion of haloperidol, resulting in a plasma concentration that isapproximately 40% lower."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302406",
      "name": "Recommendation Annotation PA166302406",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449841",
          "name": "haloperidol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103985,
        "html": "<p>The guideline does not provide a recommendation for haloperidol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on haloperidol."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "37002327",
      "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.",
      "authors": [
        "Beunk Lianne",
        "Nijenhuis Marga",
        "Soree Bianca",
        "de Boer-Veger Nienke J",
        "Buunk Anne-Marie",
        "Guchelaar Henk Jan",
        "Houwink Elisa J F",
        "Risselada Arne",
        "Rongen Gerard A P J M",
        "van Schaik Ron H N",
        "Swen Jesse J",
        "Touw Daan",
        "van Westrhenen Roos",
        "Deneer Vera H M",
        "van der Weide Jan"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2023,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37002327"
    },
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
    }
  ],
  "version": "2024-03-08-14-34"
}